Madrigal Pharmaceuticals, Inc. MDGL
We take great care to ensure that the data presented and summarized in this overview for MADRIGAL PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MDGL
View all-
Janus Henderson Group PLC London, X02.21MShares$743 Million0.36% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$687 Million38.14% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$682 Million9.12% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$670 Million10.03% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$664 Million6.75% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.71MShares$574 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.43MShares$480 Million0.01% of portfolio
-
State Street Corp Boston, MA781KShares$263 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD589KShares$198 Million0.02% of portfolio
-
Geode Capital Management, LLC Boston, MA411KShares$138 Million0.01% of portfolio
Latest Institutional Activity in MDGL
Top Purchases
Top Sells
About MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Insider Transactions at MDGL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 24
2025
|
Carole Huntsman Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
347
-3.22%
|
$116,245
$335.24 P/Share
|
|
Jan 24
2025
|
William John Sibold President and CEO |
SELL
Open market or private sale
|
Direct |
1,584
-2.83%
|
$530,640
$335.24 P/Share
|
|
Jan 24
2025
|
Rebecca Taub Pres., R&D, and CMO |
SELL
Open market or private sale
|
Direct |
648
-0.14%
|
$217,080
$335.24 P/Share
|
|
Jan 24
2025
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
103
-2.04%
|
$34,505
$335.24 P/Share
|
|
Jan 17
2025
|
Shannon T Kelley General Counsel |
SELL
Open market or private sale
|
Direct |
277
-3.47%
|
$75,621
$273.41 P/Share
|
|
Jan 17
2025
|
Rebecca Taub Pres., R&D, and CMO |
SELL
Open market or private sale
|
Direct |
1,689
-0.37%
|
$461,097
$273.41 P/Share
|
|
Jan 17
2025
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
442
-8.04%
|
$120,666
$273.41 P/Share
|
|
Dec 03
2024
|
Fred B Craves Director |
SELL
Open market or private sale
|
Indirect |
3,600
-12.8%
|
$1,134,000
$315.55 P/Share
|
|
Nov 25
2024
|
Fred B Craves Director |
SELL
Open market or private sale
|
Indirect |
3,400
-9.91%
|
$1,190,000
$350.39 P/Share
|
|
Nov 21
2024
|
Carole Huntsman Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
688
-6.0%
|
$217,408
$316.92 P/Share
|
|
Nov 07
2024
|
Richard S Levy |
SELL
Open market or private sale
|
Direct |
5,000
-31.23%
|
$1,750,000
$350.0 P/Share
|
|
Nov 07
2024
|
Richard S Levy |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+23.8%
|
$35,000
$7.36 P/Share
|
|
Nov 01
2024
|
Richard S Levy |
SELL
Open market or private sale
|
Direct |
5,000
-8.77%
|
$1,505,000
$301.97 P/Share
|
|
Nov 01
2024
|
Richard S Levy |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+23.8%
|
$35,000
$7.36 P/Share
|
|
Sep 13
2024
|
Fred B Craves Director |
SELL
Bona fide gift
|
Direct |
15,000
-4.0%
|
-
|
|
Sep 09
2024
|
William John Sibold President and CEO |
SELL
Open market or private sale
|
Direct |
6,363
-10.22%
|
$1,546,209
$243.83 P/Share
|
|
Aug 15
2024
|
Shannon T Kelley General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
5,215
+39.52%
|
-
|
|
Jun 25
2024
|
Kenneth Bate |
BUY
Grant, award, or other acquisition
|
Direct |
714
+27.19%
|
-
|
|
Jun 25
2024
|
Fred B Craves Director |
BUY
Grant, award, or other acquisition
|
Direct |
714
+0.19%
|
-
|
|
Jun 25
2024
|
Paul A Friedman |
BUY
Grant, award, or other acquisition
|
Direct |
714
+0.38%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 11.6K shares |
|---|---|
| Exercise of conversion of derivative security | 289K shares |
| Open market or private sale | 309K shares |
|---|---|
| Bona fide gift | 99.9K shares |